Two experiments were conducted to evaluate effects of ractopamine (RAC) and steroidal implant treatments on performance, carcass traits, blood metabolites, and lipogenic enzyme activity in feedlot cattle. In Exp. 1, yearling steers (n = 486; initial BW = 305 kg) were used in a 3 × 3 factorial arrangement of RAC doses of 0 (R0), 100 (R100), or 200 (R200) mg·steer −1 ·d −1 fed for 28 d and implant regimens (implant-reimplant) of no implant-no reimplant (NI-NI), 120 mg of trenbolone acetate (TBA) and 24 mg of estradiol-17β (E17B)-no implant (RS-NI), or 80 mg of TBA and 16 mg of E17B followed by 120 mg of TBA and 24 mg of E17B (RI-RS). Except for KPH and skeletal maturity score, no RAC × implant interactions were noted (P > 0.10). Carcasses from R200 were 6.3 kg (P = 0.042) heavier than those from R0. Marbling, calculated empty body fat (EBF), and USDA quality grade did not differ (P > 0.10) among RAC treatments. The RI-RS steers had 12.6 kg (P = 0.001) and 41.1 kg (P < 0.001) greater HCW than RS-NI and NI-NI, respectively. Despite no difference (P > 0.10) in EBF, marbling score was decreased for RI-RS (P < 0.001) and RS-NI (P = 0.001) relative to NI-NI, resulting in 14.6 and 11.4 percentage unit fewer USDA Prime and Choice carcasses with RI-RS (P = 0.008) and RS-NI (P = 0.039) than with NI-NI. In Exp. 2, heifers (n = 48; initial BW = 347 kg) were used in a 3 × 2 factorial arrangement of RAC doses of 0 (R0) or 250 (R250) mg·heifer −1 ·d −1 and implant regimens of none (NI), 200 mg of TBA (TO), or 200 mg of TBA and 20 mg of E17B (TE). Blood samples were collected at various times during the feeding period, and subcutaneous adipose samples were collected on d 119. For growth and carcass measurements, no RAC × implant interactions (P > 0.10) were detected. The RAC-supplemented heifers had greater HCW (P < 0.10) with no difference in marbling score. For implant regimens, TE heifers had greater HCW than the NI (P = 0.001) and TO (P = 0.037) heifers. Although EBF did not differ among implant treatments (P > 0.10), TE (P = 0.021) and TO (P = 0.039) had fewer Choice carcasses than NI. Heifers with implants had decreased cortisol and increased IGF-1 and NEFA (P < 0.10) compared with NI heifers. An implant × RAC interaction was detected (P = 0.001) for serum urea nitrogen (SUN), with TE and RAC-supplemented heifers having decreased SUN. These data suggest that the effects of implant and RAC on growth and carcass traits are independent and that USDA quality grade and marbling score can differ significantly among carcasses with similar calculated EBF values.
INTRODUCTION
As a result of repartitioning accretion of protein relative to fat, steroidal hormones, such as trenbolone acetate (TBA) and estradiol (E17B), and β-adrenergic agonists (BAA), such as ractopamine hydrochloride (RAC) and zilpaterol hydrochloride, improve production gains, efficiencies, and yield of product in beef cattle finishing programs (Laudert et al., 2005a,b; Elam et al., 2009) . Steroidal implants and BAA are believed to elicit growth responses via separate modes of action. Steroidal implants act primarily by binding to cytosolic receptors, which then act in the nucleus to stimulate gene expression and hence translation of growth-enhancing protein hormones such as IGF and GH (Gorski et al., 1990; Trenkle, 1997) . In contrast, BAA bind to cell-surface receptors to initiate signal transduction pathways and transcription of proteins such as myosin and actin, the primary proteins of skeletal muscle (Mills, 2002) . Thus, although steroidal implants and BAA appear to work through separate mechanisms, both act to increase protein deposition. As a result, negative quality attributes such as decreased tenderness and decreased quality grade have been associated with their use (Platter and Choat, 2008; Elam et al., 2009; Mehaffey et al., 2009) . It is not known whether growth responses to steroidal implants and BAA are synergistic or additive in a production setting, and no known studies have examined the interactive effects of TBA, with or without E17B, and varying doses of RAC on performance, carcass, and serial blood metabolites in feedlot cattle. Therefore, our objectives were to determine the combined effects of RAC supplementation and TBA-E17B combination implant regimens on growth performance and carcass characteristics of finishing beef cattle. A further objective was to elucidate treatment effects on serum metabolites and hormones and lipogenic activity of adipose tissue.
MATERIALS AND METHODS
Animal use, handling, and sampling techniques described herein were approved by the Colorado State University (CSU) Animal Care and Use Committee.
Exp. 1 Animals and Management.
Four hundred eighty-six yearling steers from 6 different sources were used in this study. All steers received the same basal diets for the entire experiment (Table 1 ). All diets were manufactured immediately before feeding with the on-site stationary mixer at Southeastern Colorado Research Center (SECRC). Feed was offered in sufficient quantities to allow for ad libitum intake by the cattle. Before the RAC treatment period, diets were sampled weekly, analyzed for DM determination, composited into a monthly sample, and shipped to a commercial laboratory (SDK Laboratories, Hutchinson, KS) for nutrient analysis. During the RAC-supplementation period, each of the 3 RAC treatment diets was sampled 3 times per week, composited into a weekly sample, and analyzed as described previously for monthly samples.
A supplement containing minerals, urea, vitamins, monensin (Elanco Animal Health, Greenfield, IN) , and tylosin (Elanco Animal Health) was manufactured as needed (typically weekly) at SECRC. During the RACsupplementation period, 1 of 3 additional, ground cornbased supplements was added to the respective RAC treatment diets. According to treatment, the RAC supplements were formulated to contain 0, 441, and 882 mg/kg of RAC (DM basis). All RAC treatment supplements were manufactured by Akey (Lewisburg, OH) and were shipped to SECRC 2 wk before starting the RAC treatments.
Experimental Design and Treatments. On d −1, 593 steers were weighed individually and tagged with an electronic ID tag. Steers were ranked by BW, and those that were more than 2 SD from the mean BW were excluded from the study. The remaining steers were stratified by BW into 6 BW blocks, and within each block, cattle were assigned randomly to 1 of 9 treatments resulting in 6 pens with 9 steers/pen. Treatments were arranged in a 3 × 3 factorial arrangement of treatments of RAC concentration and implant regimen. Dietary RAC concentrations were 0, 10.4, and 20.7 mg/kg (DM basis) for the 0 (control), 100, and 200 mg·steer −1 ·d −1 treatments, respectively. Implant regimens were 1) no implant and no reimplant (NI-NI; control); 2) 120 mg of TBA and 24 mg of E17B and no reimplant (RS-NI; Revalor-S, Intervet/ScheringPlough Animal Health, DeSoto, KS); and 3) 80 mg of TBA and 16 mg of E17B followed with 120 mg of TBA and 24 mg of E17B (RI-RS; Revalor-IS followed by Revalor-S, Intervet/Schering-Plough Animal Health). On d 0, steers were returned through the processing facility, individually weighed, sorted into their respective treatment pens, and the experiment was initiated.
On d 56, all steers were weighed individually, and cattle on the RI-RS treatment were reimplanted with Revalor-S. On d 112 cattle were individually weighed, and 12th-rib fat thickness was estimated via ultrasound (Aloka SSD-500, Aloka Inc., Wallingford, CT). Body weight and 12th-rib fat measurements were used to assess marketing endpoints and to set a date for the initiation of RAC feeding, which was 28 d before slaughter. Steers in all blocks received their respective RAC treatment for 28 d consecutively. Cattle were weighed individually at the start of RAC feeding and on each of the 2 d before slaughter.
Slaughter and Carcass Data Collection. Steers were slaughtered in 2 groups (blocks 5 and 6 and blocks 1 to 4) 14 d apart. On the day of slaughter, steers in each group were transported approximately 402 km to the USDA-inspected Swift and Company (now known as JBS) facility in Greeley, CO, where they were slaughtered. Carcasses were chilled at 2°C for 36 h and sprayed intermittently (each cycle consisting of 2 min on, 8 min off) with a fine mist of 2°C water for the first 8 h of the chill period. After the carcass-chilling period, a USDA grading supervisor assigned marbling and lean maturity scores to each carcass. Longissimus muscle area (LMA) measurements for each carcass were obtained by applying blotting paper (LS-601, Life Science Products, Frederick, CO) to the LM of the left side of each carcass. The outline of the LM remaining on the blotting paper was traced and subsequently scanned using software designed to measure area (MeatScan Image Analysis Software, AEW Consulting, Lincoln, NE). A panel of 2 evaluators independently evaluated each carcass and recorded measurements and assessments of adjusted fat thickness, adjusted preliminary yield grade, and skeletal maturity. Values for each trait from the 2 evaluators were averaged for each carcass. Only 1 evaluator assessed KPH. Skeletal and lean maturities were recorded on a continuous scale, with 100 = AMaturity, and 200 = B-Maturity. Marbling scores were assigned to each carcass using a continuous scale of: 300 = Traces; 400 = Slight; 500 = Small; 600 = Modest; 700 = Moderate; and 800 = Slightly Abundant. Yield grade for each carcass was calculated as 2.50 + (2.50 × adjusted fat thickness, inches) + (0.20 × KPH, %) + (0.0038 × HCW, pounds) -(0.32 × LMA, square inches). As described by Guiroy et al. (2002) Experimental Design and Treatments. On d −1, heifers were weighed individually. Heifers were ranked by BW, and within groups of 3 cattle by BW rank, were assigned randomly to 1 of 3 implant treatments (16 heifers per implant treatment): 1) NI (control), 2) 200 mg of TBA (TO; Finaplix-H, Intervet/ Schering-Plough Animal Health), or 3) 200 mg of TBA and 20 mg of E17B (TE; Revalor-200, Intervet/ Schering-Plough Animal Health). On d 0, heifers were weighed, blood samples were collected, and implant treatments were applied. Heifers were fed as a group until d 87; consequently, DMI and G:F data were not collected until the period of d 91 through slaughter. During the study, BW data were collected on d 0, 2, 7, 14, 28, 42, 56, 70, 91, 93, 98, 112, 119, and 120 . Heifers were ranked by the d-70 BW, and those that were more than 2 SD from the mean BW were excluded from the study. In addition, heifers that were not sired by 1 of the 3 Charolais bulls bred to Angus, Red Angus, and Hereford composite dams were excluded. The remaining 48 heifers were stratified by individual BW within implant treatment and randomly assigned, within BW strata, to 1 of 2 RAC treatments [0 (control) or 250 mg/heifer daily]. Ractopamine and implant treatments were arranged in a 2 × 3 factorial array. Ultimately, there were 8 BW blocks of 6 treatments for a total of 48 pens of individual animals. On d 87, cattle were sorted into their respective individual treatment pens, and RAC treatments started on d 91.
Diets. All heifers received the same basal diets for the entire experiment (Table 1) . Melengestrol acetate (MGA, Pfizer Animal Health, New York, NY) was fed to provide 0.45 mg·heifer −1 ·d −1 until d 70 of the trial, after which MGA was withdrawn because at the time the experiment was conducted, there was not an approved combination clearance for MGA and RAC.
All diets were fed once daily to allow ad libitum access to feed and were manufactured immediately before feeding in a mobile mixer at the Agriculture Research Development and Education Center. Feed was dispensed from the feed truck into plastic containers and weighed to the nearest 0.045 kg before delivery into each feed bunk.
Beginning on d 91, a separate ground corn-based supplement (0.45 kg/heifer) was administered and thoroughly mixed into daily feed issue of each animal for each treatment. The supplement for the RAC heifers was formulated to contain 551 mg/kg of RAC and 1.5% mineral oil (as-is basis), whereas the supplement for the controls had an identical formulation to that of medicated supplement, except that RAC was excluded. Ractopamine was fed for the final 29 d of the finishing period.
Finishing diet and feed commodities were sampled every 2 wk during the trial. All diet and feed commodity samples were shipped to a commercial laboratory (Servi-Tech Laboratories, Dodge City, KS) for chemical analyses.
Blood and Adipose Sampling. Corresponding to days on which heifers were weighed, blood samples (30 mL) were collected from the 48 heifers on d 0, 2, 7, 14, 28, 42, 56, 70, 91, 93, 98, 105, 112 , and 119 (defined as sampling period for subsequent statistical analysis). Jugular venipuncture was used to collect samples into both heparinized-plasma (freeze-dried sodium heparin, 158 USP units) and uncoated-serum Vacutainer tubes (Becton Dickinson, Franklin Lakes, NJ) to determine concentrations of NEFA, IGF-1, estradiol-17β, cortisol, serum urea N (SUN), epinephrine, and norepinephrine. After collection, samples were maintained on ice for 4 to 5 h before being centrifuged at 2,000 × g for 25 min at 4°C. Plasma and serum were decanted and stored in acid-washed polyethylene tubes at −80°C until analyzed.
Biopsies were sampled from the adipose tissue on d 119 from 24 of the 48 heifers. Four of the 8 blocks were chosen randomly to sample the adipose, such that all adipose samples from all animals within each of the 4 blocks were collected. Adipose tissue biopsies were obtained from the right side of the tail-head 2 d before slaughter by procedures described in Bryant et al. (2010) .
Immediately after collection and rinsing, the subcutaneous adipose tissue samples were weighed, wrapped in aluminum foil, labeled, snap-frozen in liquid N and stored at −80°C until activity of fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), and lipoprotein lipase (LPL) were determined as described in Bryant et al. (2010) .
Analytical Procedures
Serum Urea Nitrogen. Serum urea nitrogen (mg/ dL) was analyzed with a commercial kit which is based on the Berthelot reaction (Stanbio Procedure 2050, Stanbio Laboratory, Boerne, TX) using a spectrophotometer at a wavelength of 630 nm (ELx800, BioTek Instruments, Winooski, VT). The CV limit for duplicate samples was set at 5%. Inter-and intraassay CV were 9.3 and 2.1%, respectively.
Epinephrine and Norepinephrine. Plasma concentrations (pg/mL) of epinephrine and norepinephrine were analyzed with a commercial kit (3 CAT EIA, Labor Diagnostika Nord, Nordhorn, Germany; distributed by Rocky Mountain Diagnostics, Colorado Springs, CO). Absorbance was read at 450 nm with a reference wavelength of 630 nm. Interassay CV were 22.4 and 17.4% for epinephrine and norepinephrine, respectively. Because of limited quantities of plasma, intraassay comparisons were not made.
Steroid and Protein Hormones. Serum concentrations of estradiol-17β, cortisol, and IGF-1 were quantified under the direction of D. M. Hallford (Department of Animal and Range Sciences, New Mexico State University, Las Cruces). Serum E17B (pg/mL) was quantified by solid-phase RIA as described by Kane et al. (2004) , with inter-and intraassay CV of 8.8 and 3.4%, respectively. Serum cortisol (ng/mL) concentrations were determined using a commercial RIA kit as described by Kiyma et al. (2004) , with inter-and intraassay CV of 3.2 and 4.3%, respectively. Serum IGF-1 (ng/mL) was quantified in duplicate by double-antibody RIA as described by Berrie et al. (1995) using primary antisera supplied by the National Hormone and Peptide Program (Harbor-UCLA Medical Center, Torrance, CA). Assay of total serum IGF-1 was conducted after acid-ethanol inactivation of binding proteins (inter-and intraassay CV of 14.8 and 14.7%, respectively, and sensitivity of 4 ng/mL).
NEFA. Serum concentrations of NEFA (μEq/L) were analyzed by a commercially available in vitro enzymatic colorimetric procedure (NEFA-C; Wako Chemicals USA, Richmond, VA) Inter-and intraassay CV were 6.5 and 5.3%, respectively.
Slaughter and Carcass Data Collection. On the day of slaughter, heifers were transported approximately 60 km to Swift and Company (now known as JBS), Greeley, CO. Procedures, measurement scales, and calculations for carcass measurements were as described in Exp. 1, with the exception that LMA, fat area, grade percent fat, and total percent fat of the lean surface at the 12th-13th rib interface and fat thickness at the 3/4-measure opposite the lean surface between the 12th-13th rib interface were measured via the Computer Vision System Ribeye Camera (RMS Research Management Systems, USA Inc., Fort Collins, CO), which used colorimetric video-imaging. Fat area is defined as the cumulative 12th-rib fat area as measured from 6 different sections. Grade percent fat and total percent fat are adjusted and unadjusted measurements, respectively, of the area of fat within the LM. As in Exp. 1, EBF was calculated from the equations described by Guiroy et al. (2002) .
Statistical Analyses
The experimental unit in Exp. 1 and Exp. 2 was pen and animal, respectively. Analyses of growth traits and noncategorical carcass characteristics were conducted using the Mixed procedure (SAS Inst. Inc., Cary, NC). The final ANOVA model for all growth performance traits and noncategorical carcass characteristics included RAC treatment, implant treatment, and their 2-way interaction as fixed effects, with BW block as a random effect. When the overall F-value for treatment was significant (P < 0.100), least squares means were separated using the PDIFF statement in SAS.
The USDA yield and quality grade data were evaluated as categorical data (binomial proportion) using the Glimmix procedure of SAS. Ractopamine treatment, implant treatment, and the 2-way interaction between RAC and implant treatment were included in the model as fixed effects, with BW block included as a random effect.
Serum metabolite concentrations were analyzed on an individual animal basis using the Mixed procedure of SAS for a randomized block design with repeated measures as described by Littell et al. (1998) . Fixed effects included in the model were RAC treatment, implant treatment, period, and all the corresponding 2-and 3-way interactions. In addition, the blood concentration of each metabolite on d 0 was used as a covariate in the analysis. Body weight block and the 3-way interaction of block, RAC treatment, and implant treatment were included in the model as random effects. The subject effect of the repeated statement was period. A spatial power covariance structure was used with each sampling period defined in relative weeks. When the overall F-value for treatment was significant (P < 0.100), least squares means were separated using the PDIFF statement in SAS.
RESULTS AND DISCUSSION

Interactions
A primary objective was to determine the effects of RAC supplementation in combination with various implant regimens on feedlot performance and carcass traits of beef cattle and to determine whether responses to RAC and implant regimens were independent. In Exp. 1, except for KPH and skeletal maturity, no interactions between RAC supplementation and implant regimen were noted (P > 0.10), indicating that the responses associated with various implant regimens and RAC-supplementation are independent. Similarly, for growth and carcass variables, no interactions between RAC-supplementation and implant treatment were observed (P > 0.10) in Exp. 2. Consequently, this discussion will focus on the main effects of RAC supplementation and implant regimen.
Feedlot Performance-Ractopamine Supplementation
Exp. 1: Steers. Although there seemed to be a numeric trend for increased BW at slaughter associated with increasing RAC supplementation (Table 2) , no differences were detected in BW on any weigh day (P > 0.10). Steers receiving 100 and 200 mg·steer −1 ·d −1 RAC had increased (P < 0.001) ADG during the 28-d supplementation period compared with control steers. Similarly, increases of 11.1 to 27.4% in ADG in steers fed 200 mg of RAC the final 28 d of the feeding period have been reported previously Schroeder et al., 2005b) . Despite this increase, no differences in ADG (P = 0.333) over the entire feeding period were noted among the 3 RAC treatments.
Compared with the controls, steers receiving the 100 mg·steer −1 ·d −1 RAC treatments showed significant improvements in G:F ratio during the periods from the initiation of RAC treatment feeding to slaughter (P < 0.001) and from d 0 to slaughter (P = 0.077). Moreover, relative to the controls, greater increases in G:F ratio were observed in cattle on the 200 mg·steer Schroeder et al., 2005b) . Feed efficiency did not differ between steers receiving the 100 and 200 mg·steer −1 ·d −1 for any period (P > 0.10). In addition, daily DMI did not differ (P > 0.10) between RAC treatments for any period.
Exp. 2: Heifers. Before the feeding of RAC, no differences in period BW were observed (P > 0.10; Table Table 2 Ractopamine and steroidal implants in cattle 3); however, the final BW was heavier (P = 0.054) for heifers fed 250 mg of RAC/d. Results of other studies have indicated 0.7 to 1.8% increases in final BW of heifers fed 200 to 283 mg of RAC/d for 28 d Laudert et al., 2007) . In the present study, ADG during the RAC-feeding period (P = 0.001) and from d 0 to slaughter (P = 0.057) was greater for the heifers fed RAC vs. controls. The DMI did not differ during the RAC-feeding period; however, G:F was improved (P = 0.001) by feeding RAC.
Feedlot Performance-Implant Treatment Exp. 1: Steers. On d 56 (reimplant), BW of the RS-NI and RI-RS steers did not differ from each other (P = 0.784), but both were heavier (P < 0.001) than the NI-NI steers (Table 2) . At the beginning of the RAC-treatment period and increasingly at slaughter, RI-RS steers had heavier BW than RS-NI (P < 0.003) and NI-NI (P < 0.001) steers. In addition, the BW of the RS-NI cattle at the start of RAC treatments and at slaughter were greater (P < 0.001) than BW of the NI-NI cattle.
From d 0 (initial implant) to 56 (reimplant), RS-NI and RI-RS steers had similar ADG (P = 0.885) and G:F ratios (P = 0.660). However, during the same period and compared with cattle not receiving an initial implant, greater ADG (P < 0.001) was noted for the RS-NI cattle, and increased G:F was observed in the RS-NI and RI-RS groups (P < 0.001). For all other periods except for the final 28 d, differences (P < 0.10) between each implant regimen existed. For the entire feeding period, RI-RS cattle had increased ADG compared with the RS-NI (P = 0.001) and NI-NI (P < 0.001) treatments, and the RS-NI steers gained BW faster (P < 0.001) than NI-NI steers. Similarly, over the same period, increases in G:F were observed in RI-RS steers vs. RS-NI (P = 0.001) and NI-NI (P < 0.001) steers, and RS-NI steers converted feed to BW gain more efficiently (P < 0.001) than those in the NI-NI treatment. Increases in growth and efficiency associated with implanting were similar to responses noted by others (Duckett et al., 1997; Montgomery et al., 2001) .
Dry matter intake did not differ (P = 0.539) among implant treatments from d 0 to 56; however, differences (P < 0.10) in DMI were noted in all other periods. For these other periods, DMI tended to increase with increasing number of implants administered, and over the entire feeding period, the RI-RS and RS-NI cattle consumed more feed (P < 0.001) than the NI-NI cattle. Duckett et al. (1997) and Johnson et al. (1996b) reported that steroid implants typically increase DMI over a negative control treatment.
Exp. 2: Heifers. Initial and d-56 BW did not differ among implant treatments (P > 0.10); however, at the start of the RAC-feeding period, TE heifers weighed more (P = 0.007) than NI controls, and at slaughter, the TE heifers weighed more than the NI (P = 0.001) and TO heifers (P = 0.038; Table 3 ). For the entire feeding period, the ADG by TE heifers was greater than the NI (P = 0.001) and TO (P = 0.022) heifers, respectively. During the period in which intake data were collected (d 91 to slaughter), DMI was greater by the TE heifers than by the NI (P = 0.056) and TO heifers (P = 0.002), respectively; however, similar to BW gain (P > 0.10), G:F was not significantly increased (P > 0.10) with the TO and TE implants during the final 28 d of the trial.
Carcass Measurements-Ractopamine Supplementation
Exp. 1: Steers. No differences were detected (P > 0.10) between RAC-supplementation treatments for adjusted fat thickness, lean maturity, or overall maturity (Table 4) ·d −1 RAC treatment steers, respectively. Similarly, previous research has indicated −0.1 to 0.5% increases in dressing percent with RAC at 200 mg/d Schroeder et al., 2005d) . No differences in carcass weight (P = 0.733), LMA (P = 0.979), or dressing percent (P = 0.331) between the 100 mg·steer −1 ·d −1 RAC treatment and the controls were noted. Marbling and EBF (Table  4) , as well as USDA quality grade distribution and incidence of dark-cutting beef (Table 5) , did not differ (P > 0.10) among RAC treatments. Similarly, mean calculated yield grades (Table 4 ) and distribution of yield grades (Table 5 ) did not differ (P > 0.10) among RAC treatments. A RAC × implant treatment interaction was detected for KPH (P = 0.062) and skeletal maturity (P = 0.059), but reasons for these interactions are not readily evident.
Exp. 2: Heifers. Carcass data for the RAC treatments are presented in Table 6 . As expected from the live growth performance, HCW was greater (P = 0.068) for the heifers receiving 250 mg of RAC/d. Similar to the current experiment, most studies have noted a 0.3 to 1.8% increase in HCW in heifers fed 200 to 283 mg/d of RAC for 28 d Laudert et al., 2007) . Dressing percent (P = 0.992) and LMA (P = 0.250) did not differ between RAC treatments. In contrast, Schroeder et al. (2005c) and Laudert et al. (2007) reported increases in dressing percent and LMA of heifers fed 283 and 235 mg of RAC/d, respectively. In the present study, lean (P = 0.533), skeletal (P = 0.809), and overall maturities (P = 0.855) did not differ between treatments. The RAC heifers did have slightly more 12th-rib fat (P = 0.072), but KPH, calculated yield grade, and distribution of yield grades did not differ between treatments (P > 0.10). Empty body fat (P = 0.643), cumulative fat area in the LM (P = 0.392), grade percent fat (P = 0.279), and total percent fat (P = 0.336) did not differ between RAC and control treatments. Mean marbling scores were not significantly different (P = 0.266) between treatments. Schroeder et al. (2005c) and Laudert et al. (2007) noted numerical decreases in marbling score, but statistical differences were not detected. The corresponding percentage of carcasses grading USDA Choice in the present study did not differ between RAC and control heifers (P = 0.186).
Carcass Measurements-Implant Treatment
Exp. 1: Steers. Carcass weights, dressing percent, and LMA increased with increasing number of implants (Table 4 ). The RI-RS steers had heavier carcass weights than steers on the RS-NI (P = 0.001) and NI-NI (P < 0.001) implant treatments, respectively. Similarly, the RS-NI steers had heavier carcass weights (P < 0.001) than the NI controls. Dressing percent responded in a similar fashion, with the RI-RS steers having greater yields than the RS-NI (P = 0.064) and NI-NI (P < 0.001) cattle, respectively. The RS-NI cattle had a greater dressing percent (P = 0.001) than the NI-NI steers. Likewise, the RI-RS steers had a larger LM than the RS-NI (P = 0.001) and NI-NI cattle (P < 0.001), respectively, and RS-NI cattle had a larger LM (P < 0.001) than the nonimplanted controls.
Lean maturity scores decreased with increasing number of implants, with the RI-RS steers having smaller lean maturity scores (P = 0.018) than the NI-NI steers. Lean maturity for the RS-NI treatment groups did not differ from the RI-RS (P = 0.417) or the NI-NI (P = 0.101) treatments groups. As previously noted, a RAC × implant treatment interaction was noted for skeletal maturity (P = 0.059). Overall maturity was greater for the RS-NI (P = 0.001) and RI-RS (P = 0.001) treatments compared with the NI-NI treatment. A RAC × implant treatment interaction was also detected for KPH (P = 0.062).
No differences in adjusted fat thickness (P = 0.210), yield grade distributions (P > 0.334), and EBF (P = 0.369) were detected among implant regimens. On the contrary, marbling score was decreased for the RI-RS (P < 0.001) and RS-NI (P = 0.001) treatment groups relative to the NI control treatment group. As a result, the percentage of USDA Prime and Choice carcasses were numerically decreased with increasing number of implants, whereas the percentage of Select and Standard carcasses increased with increasing number of implants. Both the RI-RS (P = 0.008; 57.0%) and RS-NI steers (P = 0.039; 60.6%) had fewer carcasses grading Prime and Choice than the NI-NI steers (72.1%), but the percentage of Prime and Choice carcasses did not differ (P = 0.518) between the RS-NI and RI-RS treatment groups. Exp. 2: Heifers. The HCW was greater for the TE-treated heifers than for the NI controls (P = 0.001) and the TO cattle (P = 0.037), respectively (Table 6 ). In addition, the carcasses of the TO heifers were heavier (P = 0.067) than the nonimplanted heifers. Dressing percent did not differ (P > 0.10) among treatments. Similar to HCW, the LMA of the TE carcasses were greater than the control (P = 0.026) and TO treatments (P = 0.039). Skeletal maturity for the carcasses from the TE treatment was greater (P = 0.036) than the nonimplanted controls. Skeletal maturity did not differ (P = 0.604) between the TO and control carcasses. These results are in agreement with Exp. 1 and support previous data showing that E17B hastens ossification of cartilage to bone (Platter et al., 2003; Schneider et al., 2007) . Following a similar trend to skeletal maturity, the lean maturity of the TE carcasses was greater than that from carcasses of NI (P = 0.001) and TO-implanted heifers (P = 0.005). As a result, overall maturity of the TE carcasses was greater than in carcasses from the NI (P = 0.001) and TO (P = 0.005) heifers, and the overall maturity of the controls and TO carcasses did not differ (P = 0.318).
In agreement with the Exp. 1, EBF, a measure of compositional endpoint, did not differ among implant treatments (P = 0.585) and averaged 28.7% for the implanted heifers, which is above the critical 28% (NRC, 1996) and 28.6% (Guiroy et al., 2001 ) EBF thresholds needed to attain a USDA low-Choice quality grade. Although marbling scores did not differ (P = 0.122) among treatments, the grade percent fat (P = 0.018) and total percent fat (P = 0.026), which are 2 colorimetric measurements of marbling, were less for the TE carcasses compared with the NI controls (P < 0.10), and the total percent fat in the TE carcasses was less than the TO carcasses (P = 0.064). Moreover, the percentage of carcasses grading USDA Choice (Table 6 ) differed among treatments (P = 0.056), decreasing with increasing anabolic dose and with the concomitant addition of E17B, even though the EBF did not differ among treatments.
Numerous trials have shown that implants decrease USDA quality grade and marbling score in beef cattle (e.g., Morgan, 1997; Montgomery et al., 2001; Bruns et al., 2005) . Moreover, quality grade has been shown to decrease in a dose-dependent fashion in response to increased aggressiveness in implant regimens (Morgan, 1997; Platter et al., 2003) .
Most studies, including the current one, were conducted so that cattle were slaughtered at time-constant endpoints across treatments within block. Nichols et al. (2002) theorized that some of the negative quality aspects associated with use of steroidal agents are a result of differences in physiological endpoints and suggested that some of the decreased marbling may be negated by feeding implanted cattle longer and to Table 5 Fat area is defined as the cumulative 12th-rib fat area as measured from 6 different sections.
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Grade percent fat and total percent fat are adjusted and unadjusted measurements, respectively, of the area fat within the LM.
heavier BW. Nichols et al. (2002) also stated that at equal physiological maturity, carcass composition will be similar between implanted and NI cattle. Owens et al. (1995) suggested that EBF might be a good indicator of physiological maturity. Subsequently, Guiroy et al. (2001) developed a methodology to calculate EBF based on 12th-rib fat thickness, HCW, USDA quality grade, and LMA. Using these equations for EBF and 13 experiments that involved 15 different implant strategies, Guiroy et al. (2002) calculated the adjusted final shrunk BW at 28% EBF, which is theoretically the standard body composition needed to achieve a small degree of marbling (i.e., low Choice) on the USDA scale (NRC, 1996) . Accordingly, the BW at which animals reached the same EBF increased as the anabolic implant dose increased 14 to 42 kg and 30 to 39 kg in steers and heifers, respectively, depending on the implant regimen that is used (Guiroy et al., 2002) . Data from Exp. 1 and 2 agree with other results, such as those of Guiroy et al. (2002) , who showed that the percentages of carcasses grading USDA Choice or greater decreased even though the average EBF among implant-aggressiveness categories were similar. In addition, Guiroy et al. (2002) reported that even at a 30% EBF, many carcasses did not grade USDA Choice or greater. Schneider et al. (2007) conducted a study in heifers examining the response curves for growth and carcass measurements that were associated with increasing doses of E17B and TBA. Although the EBF among all 12 treatments were not statistically different, marbling and quality grade trended down with increasing anabolic dosage (Schneider et al., 2007) . Similarly, in reviewing the data of Roeber et al. (2000) and Platter et al. (2003) , J. D. Tatum (personal communication; Colorado State University, Fort Collins) showed that decreases in marbling score and quality grade that are associated with the use of steroidal implants were not mitigated by feeding implanted and NI cattle to the same EBF endpoint. Collectively, these results do not agree with the hypothesis of Nichols et al. (2005) , which suggested that if cattle are fed to the same EBF endpoint, they will grade similarly.
It is not clear whether the marbling and quality grade differences between the TO and TE treatments were result of differences in cumulative doses of steroid hormone or the difference in E17B content. Some have hypothesized that the ratio of E17B:TBA (Herschler et al., 1995) and more specifically the E17B portion (Gerken et al., 1995) is an important factor in the marbling effects noted in response to E17B:TBA implants. However, the comparisons in previous trials were made across different doses of both E17B and TBA, so that few relative conclusions can be drawn. More research needs to be conducted to separate the effects of cumulative anabolic dose from the effects that the E17B and TBA components have separately on performance and quality grade when they are combined in a single implant.
In agreement with the results presented in Exp. 1, the 12th-rib fat thickness, mean calculated yield grade, and yield grade distribution did not differ among implant treatments (P > 0.10). Many recent trials have noted decreased calculated yield grade and increased LMA without any differences in EBF (Platter et al., 2003; Schneider et al., 2007) or fat thickness (Platter et al., 2003; Bruns et al., 2005; Schneider et al., 2007) associated with implant use.
Blood Metabolites and Tissue Enzyme Activity
Estradiol-17β. An implant × RAC interaction was detected (P = 0.015) for serum E17B (Figure 1 ). As expected, the E17B concentration was greater in heifers that were administered an E17B-containing implant. The concentrations of E17B did not differ (P > 0.10) between NI heifers and those administered TO, regardless of whether they received supplemental RAC. Those heifers administered a TE had greater (P < 0.10) E17B concentrations than the NI or TO heifers. In agreement with others (Johnson et al., 1996b) , with current uncoated implants, the release of E17B is rapid and peaked within 7 d of administration. Newer coating technologies such as those used in the production of Revalor-XS (Intervet/Schering-Plough Animal Health) may alter the release of E17B and TBA and hence alter the patterns of protein and fat deposition observed with uncoated implants. Within the TE treatment, the heifers fed RAC had greater (P = 0.005) E17B concentrations than those that did not receive supplemental RAC. This observation cannot be explained, and no other data could be found to support or negate this finding.
Cortisol. No changes (P = 0.499) in serum cortisol concentrations were associated with feeding RAC. An implant × period interaction was detected (P = 0.007) for serum cortisol (Table 7) . For each collection period between and including d 7 and 112, serum cortisol concentrations were greater (P < 0.10) for the NI controls than for the TE heifers typically with the TO heifers being intermediate. No changes (P > 0.10) in cortisol were associated with feeding RAC. Others have also observed a decrease in circulating concentrations of serum cortisol associated with the use of E17B or TBA implants (Jones et al., 1991; Hayden et al., 1992) . In human medicine, glucocorticoids inhibit the physiological secretion of GH (Solomon and Bouloux, 2006) and decrease IGF-1 production at target organs (Schakman et al., 2008) . Moreover, Ma et al. (2001) concluded that glucocorticoids upregulate the expression of myostatin, which is a negative regulator of skeletal muscle mass, and Yang et al. (2005) suggested that glucocorticoids increase activity of the C/EBP cascade. In addition, several studies have reported that anabolic steroids can preferentially bind and displace corticosteroids from their receptors via competitive inhibition in the muscle (Trenkle, 1997; Eason et al., 2003) . As a result, it is possible that decreased secretion of glucocorticoids resulting from exposure to steroids could result in indirect anabolic effects in muscle protein.
IGF-1. No changes (P = 0.188) in IGF-1 were associated with feeding RAC suggesting that RAC does not elicit a response via the GH-IGF-1 pathway. A 2-way period × implant interaction was observed (P < 0.001) for serum IGF-1; consequently, data are summarized by implant treatment within each period (Table 7) . For every collection period from d 70 to slaughter, the IGF-1 concentrations in the TE heifers were greater (P < 0.10) than the TO and NI cattle, and the TO heifers had greater concentrations than the nonimplanted heifers. Because of the experimental design in Exp. 2, it is not known whether the apparently additive effect of E17B and TBA on circulating IGF-1 was caused by the additional anabolic dose or to the E17B component itself.
Previous research results have demonstrated that implants increase circulating IGF-1 Johnson et al., 1996a) . Hunt et al. (1991) and Mader and Kreikemeier (2006) reported increased serum IGF-1 in cattle that were given E17B in combination with TBA and observed numerical increases with E17B-or TBA-only implants compared with negative controls. It is not known whether these differences in degree of statistical significance between single-hormone implants and multiple-hormone implants were a result of the E17B component or the differences in cumulative anabolic dose.
In a review, Trenkle (1983) postulated that androgens act directly on the muscle and that E17B primarily act on the hypothalamus or anterior pituitary to increase secretion of GH. Some have reported that the relationship between E17B and GH seems to be additive, which suggests that the E17B does not solely exert actions via GH Elsasser et al., 1998) . Furthermore, Trenkle (1983 Trenkle ( , 1997 concluded that anabolic agents seem to work through more than one mechanism of action, and that the anabolic responses observed in cattle to exogenous steroids cannot be solely a result of an increase in GH secretion. Kaplan and Cohen (2007) proposed that IGF actually augment the role of GH by amplifying its anabolic actions such as increased protein synthesis and decreased proteolysis and by countering its catabolic effects such as lipolysis and gluconeogenesis. Consequently, it is likely that combination E17B and TBA implants exert responses via GH and IGF-1.
Epinephrine and Norepinephrine. No differences in plasma epinephrine (mean = 251.3 pg/mL) were detected (P > 0.10) among treatments, periods, or their interaction. A period × implant interaction was noted (P = 0.001) for plasma norepinephrine (Table  7) . On d 2, 7, 14, and 28, the NI heifers had reduced (P < 0.10) concentrations of norepinephrine than the TO heifers. In each of these collection periods, the TE heifers had intermediate plasma concentrations of norepinephrine, with reduced (P < 0.10) concentrations than the TO heifers on d 2 and 14 and greater concentrations than the controls on d 14 and 28. After d 28, no differences in plasma norepinephrine were detected (P > 0.10) among treatments. It is not known whether the intermediate response observed in the TE heifers was a result of chance or to possible mitigating effects of added E17B. No other studies could be found assessing changes in circulating catecholamine concentrations associated with steroid implant or β-adrenergic agonist use.
SUN. A RAC × implant interaction was detected (P = 0.001) for SUN concentrations (Figure 2 ). Within the nonimplanted and TO heifers, the addition of supplemental RAC decreased (P < 0.10) SUN concentrations. Within the TE treatment, no differences (P > Figure 1 . Serum concentrations of estradiol-17β (pg/mL) for each of the 6 ractopamine-implant treatment combinations across periods (Exp. 2; panel A; SE = 1.2; n = 112) and for the implant main effect by period (panel B; n = 16). Treatment abbreviations: NI = no implant; TO = trenbolone only; TE = trenbolone + estradiol; RAC = ractopamine (Elanco Animal Health, Greenfield, IN). Implant, P < 0.001; RAC, P = 0.407; implant × RAC, P = 0.015; period, P < 0.001; period × implant, P = 0.642; period × RAC, P = 0.910; implant × RAC × period, P = 0.934.
x-z Treatment combinations that do not have a common letter differ, P < 0.10. 0.10) were observed between the heifers fed RAC and those that were not fed RAC. In addition, the serum SUN concentrations of the TO-RAC did not differ (P < 0.10) from either RAC treatment of the TE heifers. The administration of an implant or supplementation or both with RAC decreased SUN, suggesting an overall net decrease in protein turnover in muscle tissue to support protein deposition.
Others have also reported a decrease in circulating SUN associated with the use of steroidal implants Mader and Kreikemeier, 2006) . With use of BAA, decreased concentrations of circulating blood urea nitrogen have been associated with the use of cimaterol (Chikou et al., 1991) and RAC (Eisemann and Bristol, 1998; Walker et al., 2006) .
NEFA. No changes (P = 0.991) in serum concentrations of NEFA were associated with feeding RAC. Circulating NEFA were increased (P < 0.10) in implanted heifers (Figure 3 ). Limited data are available examining the effects of implants on circulating NEFA. Enright et al. (1990) observed no differences in plasma NEFA of steers administered an E17B-only implant. In sheep, Lough et al. (1993) reported decreased numerical concentrations in TBA-implanted rams compared with nonimplanted controls, but the differences were not statistically different. Typically, increased concentrations of serum NEFA indicate mobilization of fat stores to provide energy support for the physiological functions of other tissues. Present findings could indicate that protein deposition and muscle building require increased energy.
In contrast to present results, several authors have reported increased concentrations of plasma NEFA in response to exposure to BAA such as cimaterol (Chikou et al., 1991; Byrem et al., 1998) , clenbuterol (Eisemann et al., 1988) , and RAC (Adeola et al., 1992) .
Lipogenic Enzyme Activity. An implant × RAC interaction (P = 0.045) was observed for FAS activity (Table 8) . Within implant treatment, the addition of RAC increased (P = 0.001) the FAS activity in the TO heifers, but no other differences were noted (P > 0.10) for the other 2 implant treatments. Across implant × RAC treatment combinations, the TO-RAC heifers had greater (P < 0.10) FAS activity than the NI-no RAC, NI-RAC, and the TO-no RAC. Similar to the FAS results, an implant × RAC interaction was detected (P = 0.043) for ACC activity. Activity of ACC did not differ (P > 0.10) between RAC treatments within the control and TE heifers; however, as with the FAS data, ACC activity increased with RAC supplementation in the TO heifers. Across treatments, the TO-RAC heifers had greater (P < 0.10) ACC activity than the TO-no RAC and either NI heifer group. No differences (P > 0.10) in implant, RAC, or their 2-way interaction were observed for LPL activity.
In agreement with the present results, Smith et al. (2007) did not detect differences in mRNA production of the lipogenic enzymes ACC, LPL, and stearoyl-CoA desaturase between cattle that either did not receive an anabolic implant and those that received 2 separate doses of 28 mg of estradiol benzoate and 200 mg of TBA during the feeding period. More recently, Parr et Means in the same row within main effect and hormone that do not have a common superscript letter differ, P < 0.10. Implant, P = 0.002; ractopamine (Elanco Animal Health, Greenfield, IN), P = 0.499; implant × ractopamine, P = 0.569; period, P < 0.001; period × implant, P = 0.007; period × ractopamine, P = 0.696; implant × ractopamine × period, P = 0.812; SE = 3.3; n = 16. 3 Implant, P < 0.001; ractopamine, P = 0.188; implant × ractopamine, P = 0.715; period, P < 0.001; period × implant, P < 0.001; period × ractopamine, P = 0.310; implant × ractopamine × period, P = 0.173; SE = 21.4; n = 16. al. (2008) reported that after 28 d of exposure, finishing steers implanted with 24:120 mg of E17B:TBA had decreased abundance of PPARγ and stearoyl CoA desaturase mRNA and a tendency for decreased C/EBPβ mRNA expression, transcription factors, and enzymes that are involved in lipogenesis. Singh et al. (2003) reported that testosterone and dihydrotestosterone downregulated C/EBPα and PPARγ mRNA expression in pluripotent mesenchymal cells.
In relation to RAC, some reports have indicated decreased lipogenesis of porcine adipocytes (Mills et al., 1990; Peterla and Scanes, 1990) ; however, Liu et al. (1994) observed no difference in the activity of ACC or malic enzyme in the subcutaneous adipose tissue of pigs fed RAC. In ruminants fed BAA, Hu et al. (1988) reported increased lipogenesis in sheep fed cimaterol, whereas Miller et al. (1988) reported decreased lipogenic enzyme activity in heifers fed clenbuterol. The inconclusive results in the current study may partially result from the fact that samples were taken from subcutaneous adipose depot. In cattle, our results and other published data have rarely indicated differences in 12th-rib fat thickness when BAA are fed, whereas differences in quality grade have been reported. In addition, samples were taken after RAC had been feed for 28 d, and the majority of the physiological response had already occurred. Further research should be conducted to determine the time-course changes in lipogenesis in the intramuscular adipose pool when RAC and other BAA are fed. Based on our results and previous findings in the literature, however, the effect of BAA on lipogenesis might depend on species, body composition, timing relative to the initiation of BAA feeding, and tissue specificity, including differences between subcutaneous and intramuscular pools.
Overall Conclusions
Results of the present experiments suggest that steroidal implants and RAC can act additively to alter growth and carcass performance. Moreover, USDA quality grade and marbling score can differ despite cattle being slaughtered at equal EBF. To determine compositional endpoints at which quality grade will be equivalent, new equations with independent slopes and intercepts must be modeled from implant trial data instead of applying existing equations to trial results. Further research should be initiated to evaluate the dose equivalencies of E17B and TBA to determine whether 2). Implant, P = 0.043; ractopamine (Elanco Animal Health, Greenfield, IN), P = 0.99; implant × ractopamine, P = 0.814; period, P < 0.001; period × implant, P = 0.798; period × ractopamine, P = 0.288; implant × ractopamine × period, P = 0.138.
x,y Treatment combinations that do not have a common letter differ, P < 0.10 (SE = 9.5; n = 224). these components individually have differential effects on growth and carcass quality. Combination implants seem to elicit action via GH and IGF-1 pathways and also seem to increase lipolysis without affecting lipogenesis. Furthermore, as measured by classical metabolite indicators of growth and protein and fat anabolism and catabolism, steroids and BAA seem to elicit dissimilar metabolic responses, suggesting different modes of action. Further research is needed to elucidate the mechanisms of action of both steroidal implants and BAA at both the cellular level and in terms of changes in organ mass. Table 8 
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